Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and...

Details Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and... Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and...

2005-10-18

2005-10-18

Barts, Samuel (Department: 1621)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Nitrogen containing other than solely as a nitrogen in an...

C514S647000

Reexamination Certificate

active

06956060

ABSTRACT:
The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an effective illness, a neurodegenerative disease, a neurotoxic injury, stroke, brain ischemia, a head trauma injury, a spinal trauma injury, neurotrauma, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject. Finally, the subject invention provides methods of preparing R(+)-N-propargyl-1-aminoindan, a salt thereof, and racemic N-propargyl-1-aminoindan.

REFERENCES:
patent: 3201470 (1965-08-01), Huebner
patent: 3253037 (1966-05-01), Huebner
patent: 3513244 (1970-05-01), Gittos et al.
patent: 4826875 (1989-05-01), Cheisi
patent: 4855326 (1989-08-01), Fuisz
patent: 4971995 (1990-11-01), Schoofs et al.
patent: 5043347 (1991-08-01), Clemence et al.
patent: 5079018 (1992-01-01), Ecanow
patent: 5137730 (1992-08-01), Dennis et al.
patent: 5196583 (1993-03-01), Yamada et al.
patent: 5225197 (1993-07-01), Bolt et al.
patent: 5298261 (1994-03-01), Pebley et al.
patent: 5387612 (1995-02-01), Youdim et al.
patent: 5453446 (1995-09-01), Youdim et al.
patent: 5457133 (1995-10-01), Youdim et al.
patent: 5466464 (1995-11-01), Masaki et al.
patent: 5486541 (1996-01-01), Sterling et al.
patent: 5519061 (1996-05-01), Youdim et al.
patent: 5532415 (1996-07-01), Youdim et al.
patent: 5576353 (1996-11-01), Youdim et al.
patent: 5599991 (1997-02-01), Youdim et al.
patent: 5668181 (1997-09-01), Youdim et al.
patent: 5744500 (1998-04-01), Youdim et al.
patent: 5786390 (1998-07-01), Youdim et al.
patent: 5792473 (1998-08-01), Gergely et al.
patent: 5891923 (1999-04-01), Youdim et al.
patent: 6126968 (2000-10-01), Peskin et al.
patent: 6316504 (2001-11-01), Youdim et al.
patent: WO 9215551 (1992-09-01), None
patent: 0252290 (1989-02-01), None
patent: 0303961 (1989-02-01), None
patent: 0538134 (1993-04-01), None
patent: 0436492 (1994-06-01), None
patent: WO 9108201 (1991-06-01), None
patent: 1003686 (1965-09-01), None
patent: 1037014 (1966-07-01), None
patent: 1187017 (1970-04-01), None
patent: 1548022 (1979-07-01), None
patent: WO 9626720 (1996-09-01), None
patent: WO 9712583 (1997-04-01), None
patent: WO 9802152 (1998-01-01), None
patent: 3500897 (1991-02-01), None
patent: 6408887 (1965-02-01), None
patent: WO 9411567 (1994-05-01), None
patent: WO 9104479 (1991-04-01), None
patent: WO 9511016 (1995-04-01), None
patent: WO 9637199 (1996-11-01), None
patent: WO 9001928 (1990-03-01), None
patent: WO 9104757 (1991-04-01), None
patent: WO 9312769 (1993-04-01), None
patent: WO 9325197 (1993-12-01), None
patent: WO 8804552 (1999-06-01), None
U.S. Appl. No. 10/679,672, filed Oct. 6, 2003, Youdim et al.
U.S. Appl. No. 10/903,081, filed Jul. 30, 2004, Youdim et al.
Harris et al., “Drug Delivery via the Mucous Membranes of the Oral Cavity”, J. Pharm. Sciences, 1992, 81(1):1-10 (Exhibit 17).
Heinonen et al., “Pharmacokinetic Aspects of 1-deprenyl (Selegiline) and its Metabolites”,Clin. Pharmacol.&Therapeutics,1994, 56(6-2):742-749 (Exhibit 18).
Epsztein et al., “Synthese De Bases De Mannich Acetyleniques Cycliques”,Tetrahedron Letters,1985, 26(27): 3203-3206.
Finberg and Youdim, “Modification of Blood Pressure and Nictitating Membrane Response to Sympathetic Amines by Selective Monoamine Oxidase Inhibitors,”Brit. J. Pharmac,1985, 85(2): 541-546.
Finberg et al., “Selective Irreversible Propargyl Derivative Inhibitors of Monoamine Oxidase (MAO) without the Cheese Effect”,Chem. Abstracts,1981, 94:202499.
Finberg et al., “Modification of Blood Pressure and Nictitating Membrane Response to Sympathetic Amides by Selective Monomide Oxidase Inhibitors, Types A and B, in the Cat”,Chem. Abstracts,1985, 103: 81618.
Heikkila et al., “Prevention of MPTP-Induced Neurotoxicity by AGN-1133 and AGN-1135, Selective Inhibitors of Monoamine Oxidase-B”,Eur. J. Pharmacol.,1985, 116:313-317.
U.S. Appl. No. 10/016,268, filed Oct. 26, 2001, Youdim et al.
Kabins and Gershon, “Potential Applications for Monoamine B Inhibitors”,Dementia,1990, 1: 323-348.
Kalir et al., “Selective Acetylenic ‘Suicide’ and Reversible Inhibitors of Monoamine Oxidase Types A and B”,Chem. Abstracts,1981, 95:110796.
Maruyama et al., “Cyclization Reaction of N-Propargyl Epoxyamide to Acetylenic 2-Azetidinone, a Precursor to Thienamycin and Related Carbapenems”,Tetrahedron Letters,1985, 26 (37): 4521-4522.
Riederer and Youdim, “Monoamine Oxidase Activity and Monoamine Metabolism in Brains of Parkinson's Patients Treated withl-Deprenyl” J. Neurochem.,1986, 46(5): 1359-1365.
Tariot et al., “L-Deprenyl in Alzheimer's Disease: Preliminary Evidence for Behavioral Change with Monoamine Oxidase B Inhibition”,Biological Abstracts,1987, 84: 18676.
Tekes et al., “Effect of MAO Inhibitors on the Uptake and Metabolism of Dopamine in Human and Rat Brains”,Pol. J. Pharmacol. Pharm.,1988, 40: 654-658.
Youdim et al., “Monamine Oxidase” inHandbook of Experimental Pharmacology,vol. 90/I, 1988, Chapter 3, Trendelenburg and Weiner, eds.
The Merck Index, (11thEdition, 1989) Merck and Co., Inc., Rahway, N.J. 164, 272, 860-861.
The Merck Index (10thed., 1983) Merck & Co., Inc., Rahway, N.J., 149, 248-249.
The Parkinson Study Group, “Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease”,New Eng. J. Med.,1993, 328 (3): 176-183.
The Parkinson Study Group, “Effect of Deprenyl on the Progression of Disability in Early Parkinson's Disease”,New Eng. J. Med,1989, 321(20): 1364-1371.

Affiliated with

Also associated with

Rating

Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3480057